Hemophilia B treatment gains orphan-drug designation

The FDA granted orphan-drug status to CSL Behring's recombinant fusion protein linking coagulation factor IX with recombinant albumin to prevent and treat bleeding episodes in patients with hemophilia B. Pharmaceutical Business Review Online

Source: AABBsmartbrief